Breast Neoplasm Clinical Trial
Official title:
Detection of Folate Receptor-positive Circulating Tumor Cells as a Biomarker for Diagnosis
A prospective study was used to collect patients considering breast cancer admitted to our general surgery department from 2019-6 to 2023-8, to identify the case group (breast cancer) and the control group (non-breast cancer), to compare the differences in CTC in peripheral blood between the two groups, and to draw conclusions after statistical analysis.
This project is a prospective study by collecting clinical data from breast cancer and non-breast cancer patients admitted to our general surgery department from 2020 to 2023, and drawing peripheral blood for CTC testing. The clinical data of 200 patients were initially collected and grouped, with the study group positioned as breast cancer patients (patients with pathologically determined breast cancer) and the control group as non-breast cancer patients (patients with benign breast tumors and healthy women), to investigate the expression of CTC in breast cancer and correlation with the degree of metastasis, as well as to further understand the relationship between CTC in peripheral blood and breast cancer clinicopathology. The circulating tumor cell enrichment was compared between the two groups, and the data were derived for statistical analysis to draw conclusions, as well as to identify shortcomings and make improvements to the existing problems. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03273426 -
Prediction of pCR by Preoperative Biopsy in Breast Cancer With cCR After Neoadjuvant Chemotherapy.
|
N/A | |
| Recruiting |
NCT04583124 -
Adjusting the Dose of Therapeutic Exercise to Prevent Neurotoxicity Due to Anticancer Treatment (ATENTO)
|
N/A | |
| Recruiting |
NCT04489173 -
TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT02913573 -
Effect of Pectoral Nerve Block on Post-op Pain in Patients Undergoing Mastectomy and Immediate Reconstruction
|
Phase 2 | |
| Completed |
NCT03124095 -
Combined Training Intervention for Women Who Underwent Primary Treatment for Breast Cancer
|
N/A | |
| Terminated |
NCT00251095 -
Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer
|
Phase 3 | |
| Completed |
NCT05576545 -
Develop and Evaluate the Effectiveness of a Self-Care Smartphone Application on the Self-Efficacy, and Resilience Among Newly Diagnosed Breast Cancer Patients Undergoing Treatment
|
N/A | |
| Active, not recruiting |
NCT03625635 -
Effect of a Clinical Nutrition Intervention Program in Breast Cancer Patients During Antineoplastic Treatment
|
N/A | |
| Recruiting |
NCT04799535 -
Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
|
||
| Withdrawn |
NCT03266562 -
Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography
|
N/A | |
| Completed |
NCT00530868 -
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT06255808 -
Development of Assist Tool for Breast Examination Using the Principle of Ultrasonic Sensor
|
||
| Completed |
NCT04640220 -
Improvement of Range of Motion in Frozen Shoulder in Breast Cancer Survivors
|
N/A | |
| Completed |
NCT02970682 -
SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT02316561 -
Single Dose Ablative Radiation Treatment for Early-Stage Breast Cancer
|
N/A | |
| Terminated |
NCT00638963 -
Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
|
Phase 2 | |
| Terminated |
NCT00249301 -
A Study of MLN8054 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06056414 -
Study of Anxiety After a Session of Energy Resonance by Cutaneous Stimulation
|
N/A | |
| Recruiting |
NCT05427071 -
Magnetic Marker Localization for Occult Breast Cancer and Target Axillary Dissection in Node-positive Breast Cancer Post-neoadjuvant Chemotherapy
|
N/A | |
| Recruiting |
NCT03740893 -
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer
|
Phase 2 |